-
公开(公告)号:US09440924B2
公开(公告)日:2016-09-13
申请号:US14236608
申请日:2012-07-31
IPC分类号: C07D223/16
CPC分类号: C07D223/16
摘要: The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.
摘要翻译: 本发明涉及盐酸伊伐布拉定的新型溶剂合物,其制备方法及其在制备盐酸伊伐布雷定特异性多晶型物中的应用。
-
公开(公告)号:US08435998B2
公开(公告)日:2013-05-07
申请号:US12993351
申请日:2009-06-25
IPC分类号: A61K31/496 , C07D405/14
CPC分类号: C07D405/06 , C07D405/14
摘要: The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.
摘要翻译: 本发明涉及泊沙康唑的结晶形式IV及包含其的药物组合物。 药物组合物可用于治疗或预防真菌感染。
-
公开(公告)号:US08222380B2
公开(公告)日:2012-07-17
申请号:US12159939
申请日:2007-01-04
IPC分类号: C07H17/08
CPC分类号: C07H17/08
摘要: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.
摘要翻译: 本发明涉及稳定的无定形3-De [(2,6-二脱氧-3-C-甲基-3-O-甲基-α-L-核糖-6-吡喃糖基)氧基] -11,12-二脱氧-6-O-甲基 -3-氧代-12,11- [氧羰基[[4- [4-(3-吡啶基)-1H-咪唑-1-基]丁基]亚氨基]]红霉素(泰利霉素),其制备方法, 稳定的非晶泰利霉素治疗细菌感染和包含稳定的非晶泰利霉素的药物组合物。
-
4.
公开(公告)号:US20110105525A1
公开(公告)日:2011-05-05
申请号:US12993297
申请日:2009-05-28
申请人: Josef Wieser , Arthur Pichler , Andreas Hotter , Ulrich Griesser , Christoph Langes , Christian Laschober
发明人: Josef Wieser , Arthur Pichler , Andreas Hotter , Ulrich Griesser , Christoph Langes , Christian Laschober
IPC分类号: A61K31/496 , C07D405/14 , A61P31/10
CPC分类号: A61K31/496
摘要: The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.
摘要翻译: 本发明涉及包含泊沙康唑的晶形Y的药物组合物。 药物组合物可用于治疗或预防真菌感染。
-
公开(公告)号:US20110015191A1
公开(公告)日:2011-01-20
申请号:US12528483
申请日:2008-02-22
IPC分类号: A61K31/5377 , C07D413/06 , A61P1/08
CPC分类号: C07D413/06
摘要: Novel polymorph form III of Aprepitant and a method for preparation of novel form III is disclosed. New processes for the preparation of Aprepitant form II are disclosed. The processes involve transformation of form III to form II by heating in decalin and the precipitation of form II from a solvent or solvent mixture by cooling and/or addition of addition of seed crystals or an anti solvent. Solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A process for the preparation of the solid dispersion by evaporation of a solution of Aprepitant and the carrier in a suitable solvent is disclosed. Stable Aprepitant form II is disclosed. Further pharmaceutical compositions containing Aprepitant form II, III or solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A methanol solvate of Aprepitant is disclosed.
摘要翻译: 公开了Aprepitant的新型多晶型III和新型III的制备方法。 公开了制备Aprepitant II型的新方法。 所述方法包括通过在十氢化萘中加热和通过冷却和/或加入晶种或抗溶剂从溶剂或溶剂混合物中沉淀形式II而转化成形式II。 公开了在合适的载体中含有形式II的固体分散体。 公开了通过在适当溶剂中蒸发阿维地丁和载体溶液来制备固体分散体的方法。 公开了稳定的Aprepitant II型。 公开了另外的药物组合物,其中含有Aprepitant形式II,III或在合适的载体中含有Aprepitant II型的固体分散体。 公开了一种甲酸溶剂化物的Aprepitant。
-
公开(公告)号:US20090099370A1
公开(公告)日:2009-04-16
申请号:US11990351
申请日:2006-08-10
IPC分类号: C07D209/42
CPC分类号: C07D209/42
摘要: The present invention relates to new crystalline form of the ACE inhibitor perindopril and processes for the preparation thereof.
摘要翻译: 本发明涉及ACE抑制剂培哚普利的新结晶形式及其制备方法。
-
公开(公告)号:US20080132518A1
公开(公告)日:2008-06-05
申请号:US11795909
申请日:2006-01-27
IPC分类号: A61K31/496 , C07D295/00 , A61P25/18
CPC分类号: C07D215/227
摘要: The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.
摘要翻译: 本发明涉及阿立哌唑的新型多晶型及其制备方法。 它还涉及包含新颖形式的药物组合物以及新型形式在治疗精神分裂症中的用途。
-
公开(公告)号:US20140336179A1
公开(公告)日:2014-11-13
申请号:US14236608
申请日:2012-07-31
IPC分类号: C07D223/16
CPC分类号: C07D223/16
摘要: The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.
摘要翻译: 本发明涉及盐酸伊伐布拉定的新型溶剂合物,其制备方法及其在制备盐酸伊伐布雷定特异性多晶型物中的应用。
-
公开(公告)号:US09266868B2
公开(公告)日:2016-02-23
申请号:US13805462
申请日:2011-07-05
申请人: Johannes Ludescher , Hubert Sturm , Ulrich Griesser , Robert E. Ziegert-Knepper , Arthur Pichler , Mairi Haddow
发明人: Johannes Ludescher , Hubert Sturm , Ulrich Griesser , Robert E. Ziegert-Knepper , Arthur Pichler , Mairi Haddow
IPC分类号: C07D413/12 , C07D413/14
CPC分类号: C07D413/12 , C07D413/14
摘要: Provided are a crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions containing the crystalline dihydrate and processes for preparing and storing the pharmaceutical compositions. Also provided are a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and the use of the Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.
摘要翻译: 提供了Rivaroxaban的结晶二水合物,其制备方法,含有结晶二水合物的药物组合物以及制备和储存药物组合物的方法。 还提供了Rivaroxaban的结晶甲酸溶剂化物,制备结晶Rivaroxaban甲酸溶剂化物的方法,以及使用Rivaroxaban甲酸溶剂合物制备Rivaroxaban结晶二水合物。
-
公开(公告)号:US08946441B2
公开(公告)日:2015-02-03
申请号:US13702077
申请日:2011-06-24
IPC分类号: C07D277/00 , A61K31/425 , C07D277/56
CPC分类号: C07D277/56
摘要: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
摘要翻译: 本发明涉及非索非斯坦的结晶形式I以及包含结晶形式I作为活性药物成分的药物组合物。 此外,本发明还涉及另一种指定为II型的异丙酚钠的多晶型物,还涉及一种新颖的非索非司他溶剂合物。 本发明还涉及制备结晶形式I,形式II和新戊酸钠的新型溶剂合物的方法。
-
-
-
-
-
-
-
-
-